Etanercept

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
84
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Spondylarthropathies, Enthesitis

Conditions

Spondylarthropathies, Enthesitis

Trial Timeline

Jan 1, 2007 โ†’ Sep 1, 2008

About Etanercept

Etanercept is a approved stage product being developed by Pfizer for Spondylarthropathies, Enthesitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00420303. Target conditions include Spondylarthropathies, Enthesitis.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (20)

NCT IDPhaseStatus
NCT00063869Phase 2Completed
NCT04507776Pre-clinicalCompleted
NCT04507763Pre-clinicalCompleted
NCT04267614Pre-clinicalCompleted
NCT02656082Phase 2Completed
NCT02509026ApprovedCompleted
NCT02378506Phase 3Completed
NCT02486302Pre-clinicalCompleted
NCT02322580Pre-clinicalCompleted
NCT01421069Phase 3Completed
NCT01068353Phase 2Completed
NCT01793285Pre-clinicalCompleted
NCT01100034Pre-clinicalCompleted
NCT00913458ApprovedCompleted
NCT00962741Phase 3Completed
NCT00910273ApprovedTerminated
NCT00768053ApprovedCompleted
NCT00705042Phase 1Completed
NCT00544557Pre-clinicalCompleted
NCT00581555ApprovedCompleted

Competing Products

3 competing products in Spondylarthropathies, Enthesitis

See all competitors
ProductCompanyStageHype Score
SecukinumabNovartisPhase 3
77
MethotrexateOrion CorporationApproved
82
etoricoxib + Other COX-2 inhibitor + nsNSAIDsOrganonPre-clinical
18